160911-15-9

Upstream product

• 253268-25-6 4,6-dichloro-3-hydroxy-2-nitrobenzoic acid 
• 253268-23-4 2,4-dichloro-5-methoxyphenyl trifluoromethanesulfonate 
• 253268-24-5 methyl 2,4-dichloro-5-methoxybenzoate 
• 91659-09-5 2,4-dichloro-5-hydroxybenzoic acid 
• 18113-13-8 2,4-dichloro-5-methoxyphenol 

Downstream Products

• 1232842-59-9 4,6-dichloro-2-(2-chloroacetamido)-3-hydroxybenzoic acid 
• 866244-91-9 4,6-dichloro-2-formylamino-3-hydroxybenzoic acid 
• 866244-92-0 2-amino-4,6-dichloro-3-hydroxy-N-(n-propyl)benzamide 

Relevant academic research and scientific papers

QUINAZOLINONE COMPOUNDS

The present invention relates to quinazolinone compounds, processes for their preparation and their use as pharmaceutical agents for the treatment of Parkinson's disease (PD). The quinazolinone compounds are of general formula (I).

NEUROLOGICALLY-ACTIVE COMPOUNDS

Neurologically-active heterocyclic compounds comprising two fused 6-membered rings with nitrogen atoms at positions 1 and 3, a carboxy group at position 4,and a hydroxy group at position 8, with one ring being aromatic. Processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, and more specifically neurodegenerative conditions such as Alzheimer's disease.

Synthesis and QSAR of substituted 3-hydroxyanthranilic acid derivatives as inhibitors of 3-hydroxyanthranilic acid dioxygenase (3-HAO)

Novel 4,5-, 4,6-disubstituted and 4,5,6-trisubstituted 3- hydroxyanthranilic acid derivatives were synthesized and their ability to reduce the production of the excitotoxin quinolinic acid (QUIN) by inhibition of brain 3-hydroxyanthranilic acid dioxygenase (3-HAO) was subsequently investigated. The potency of the compounds to inhibit 3-HAO was assayed in rat brain homogenate, while chemical stability of certain compounds was studied by HPLC. The data were used to generate quantitative structure- activity relationship (QSAR) models for potency of 3-HAO inhibition and compound stability. Compounds with longer half-lives were obtained when the difference between the HOMO and LUMO was increased, while electron withdrawing groups in the 4- and 5-positions increased the potency of 3-HAO inhibition. Selected compounds that showed high potency in vitro were also found to be efficacious inhibitors in vivo after cerebral administration in rats.

NEW COMPOUNDS

The present invention relates to novel derivatives of 3-hydroxyanthranilic acid, 3-HANA, of the general formula I wherein R1 and R2 are the same or different and selected from H, alkyl, aryl and arylalkyl; X and Y are the same or different and selected fr